ClinicalTrials.gg
TerminatedNCT03505710DESTINY-Lung01Updated May 30, 2025Results posted

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

A Phase 2 interventional study of Trastuzumab deruxtecan in Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo. Terminated at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Why this study was terminated
Last participant transitioned to alternative study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 12
181 · median 167
Started
2018
the only one that year
Phase 2
7 of 12
2 open now
Registered
2nd of 12
by date
Lead sponsor
4 of 12
Daiichi Sankyo

Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • HER2 over-expression
  • HER2 mutation
  • Unresectable or metastatic
  • Non-squamous
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥20 years old in Japan, ≥18 years old in other countries
  • documented unresectable and/or non-squamous NSCLC
  • Has from or is refractory to standard treatment or for which no standard treatment is available
  • For Cohort 1 and Cohort 1a: -overexpression (IHC 2+ or 3+) status must be assessed and confirmed by Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or equivalent, from an sample
  • For Cohort 2 only: Participant has any known documented activating HER2 mutation from an archival tumor tissue sample analyzed by CLIA laboratory or equivalent. Note: HER2 mutation documented only from a liquid biopsy sample cannot be used for enrollment.
  • Presence of at least 1 assessed by the investigator and based on (RECIST) version 1.1
  • Is willing and able to provide an adequate archival tumor tissue sample
  • Is willing to undergo a tissue biopsy, after the completion of the most recent treatment regimen
  • Has Performance Status (ECOG PS) of 0 to 1

Exclusion criteria

Exclusion Criteria:

  • Had been previously treated with -targeted therapies, except for pan-HER class tyrosine kinase inhibitors
  • For Cohort 1 and Cohort 1a: Has known HER2 mutation
  • Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) ( classes II-IV), unstable angina or serious cardiac arrhythmia
  • Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required , or current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out due to imaging at screening
  • Has a corrected by Fridericia's formula (QTcF) prolongation to > 450 millisecond (ms) in males and > 470 ms in females
  • Has a medical history of lung disease
  • Is suspected to have certain other protocol-defined diseases based on imaging at screening period
  • Has history of any disease, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:

    1. safety or well-being of the participant or offspring
    2. safety of study staff
    3. analysis of results
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Cohort 1: HER2 Overexpressing

    Participants with HER2-overexpressing(immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).

    Drug: Trastuzumab deruxtecan

  • Experimental
    Cohort 1a: HER2 Overexpressing

    Participants with HER2-overexpressing (immunohistochemistry \[IHC\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).

    Drug: Trastuzumab deruxtecan

  • Experimental
    Cohort 2: HER2 Mutated

    Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).

    Drug: Trastuzumab deruxtecan

Interventions

  • Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.

    Also known as: DS-8201a, Experimental product

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.

    Time frame: From screening, up to 36 months (data cut-off)

Secondary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on investigator assessment is reported.

    Time frame: From screening, up to 36 months (data cut-off)

  2. Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported.

    Time frame: From screening to documented tumor progression or death from any cause, up to 36 months (data cut-off)

  3. Progression-Free Survival (PFS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported.

    Time frame: From date of enrollment to first objective radiographic tumor progression or death from any cause,, up to 36 months (data cut-off)

  4. Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.

    Time frame: From date of enrollment to death from any cause, up to 36 months (data cut-off)

  5. Percentage of Participants With Disease Control Rate (DCR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

    Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported.

    Time frame: From first dose, up to 36 months (data cut-off)

07

Results

Posted May 17, 2022

Participant flow

A total of 181 participants were enrolled and treated at clinic centers in Japan, United States, France, Netherlands, and Spain.

Participant flow — Overall Study
MilestoneCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Started494191
Completed000
Not completed494191
Withdrew: Progressive disease241743
Withdrew: Clinical progression683
Withdrew: Adverse event12628
Withdrew: Withdrawal by subject137
Withdrew: Physician decision112
Withdrew: Death456
Withdrew: Other reasons111
Withdrew: Study terminated by sponsor001

Outcome measures

PrimaryPercentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

The Objective Response Rate (ORR) was the defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by independent central review (ICR) committee based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on ICR is reported.

Time frame:
From screening, up to 36 months (data cut-off)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Percentage of ParticipantsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)26.5 (15.0 to 41.1)34.1 (16.1 to 45.5)54.9 (44.2 to 65.4)
SecondaryPercentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on investigator assessment is reported.

Time frame:
From screening, up to 36 months (data cut-off)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Percentage of ParticipantsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)28.6 (16.6 to 43.3)31.7 (18.1 to 48.1)61.5 (50.8 to 71.6)
SecondaryDuration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on independent central review and investigator assessment is reported.

Time frame:
From screening to documented tumor progression or death from any cause, up to 36 months (data cut-off)
Reported as:
Median · months
Duration of Response (DoR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
monthsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Independent Central Review5.8 (4.3 to NA)4.7 (4.0 to NA)9.3 (5.7 to 14.7)
Investigator Assessment5.8 (4.7 to 11.3)7.0 (4.2 to NA)11.7 (7.2 to 16.9)
SecondaryProgression-Free Survival (PFS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported.

Time frame:
From date of enrollment to first objective radiographic tumor progression or death from any cause,, up to 36 months (data cut-off)
Reported as:
Median · months
Progression-Free Survival (PFS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
monthsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Independent Central Review5.7 (2.8 to 7.2)6.7 (4.5 to NA)8.2 (6.0 to 11.9)
Investigator Assessment5.7 (3.8 to 7.2)7.2 (4.1 to 8.4)9.3 (7.1 to 14.0)
SecondaryOverall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.

Time frame:
From date of enrollment to death from any cause, up to 36 months (data cut-off)
Reported as:
Median · months
Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
monthsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Overall Survival (OS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)12.4 (7.8 to 17.2)NA (6.7 to NA)17.8 (13.8 to 22.1)
SecondaryPercentage of Participants With Disease Control Rate (DCR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

Disease Control Rate (DCR) was defined as the percentage of participants who achieved a best overall response of CR, PR, or stable disease (SD) during study treatment. Confirmation of CR/PR was required. DCR based on independent central review and investigator assessment is reported.

Time frame:
From first dose, up to 36 months (data cut-off)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Control Rate (DCR) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)
Percentage of ParticipantsCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Independent Central Review68.9 (53.4 to 81.8)77.5 (61.6 to 89.2)93.0 (85.4 to 97.4)
Investigator Assessment75.5 (61.1 to 86.7)78.0 (62.4 to 89.4)94.5 (87.6 to 98.2)

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: HER2 Overexpressing42/49 (85.7%)28/49 (57.1%)46/49 (93.9%)
Cohort 1a: HER2 Overexpressing32/41 (78%)18/41 (43.9%)41/41 (100%)
Cohort 2: HER2 Mutated72/91 (79.1%)40/91 (44%)91/91 (100%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
Disease ProgressionGeneral disorders6/494/417/91
DyspnoeaRespiratory, thoracic and mediastinal disorders5/492/411/91
PneumonitisRespiratory, thoracic and mediastinal disorders4/492/417/91
PneumoniaInfections and infestations4/491/412/91
HypoxiaRespiratory, thoracic and mediastinal disorders0/492/411/91
Respiratory Tract InfectionInfections and infestations1/492/410/91
NauseaGastrointestinal disorders2/490/411/91
VomitingGastrointestinal disorders1/491/413/91
SeizureNervous system disorders1/490/413/91
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders0/490/413/91
Most frequent other events
Showing 10 of 69
Most frequent other events
EventCohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 Mutated
NauseaGastrointestinal disorders28/4930/4169/91
FatigueGeneral disorders16/4921/4130/91
FatigueGastrointestinal disorders16/4920/4130/91
Decreased AppetiteMetabolism and nutrition disorders22/4919/4132/91
VomitingGastrointestinal disorders14/4913/4142/91
AlopeciaSkin and subcutaneous tissue disorders10/495/4142/91
DiarrhoeaGastrointestinal disorders13/4914/4139/91
ConstipationGastrointestinal disorders15/4910/4136/91
AnaemiaBlood and lymphatic system disorders15/4913/4133/91
CoughRespiratory, thoracic and mediastinal disorders7/4913/4118/91

Baseline characteristics

Baseline characteristics were assessed using the Safety Analysis Set.

Age, Categorical
Age, Categorical(Participants)Cohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 MutatedTotal
<=18 years0000
Between 18 and 65 years272755109
>=65 years22143672
Age, Continuous
Age, Continuous(Years)Cohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 MutatedTotal
Mean62.2 ± 9.5860.3 ± 10.2260.3 ± 11.9460.8 ± 10.94
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 MutatedTotal
Female19196098
Male30223183
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 MutatedTotal
American Indian or Alaska Native0101
Asian1343148
Native Hawaiian or Other Pacific Islander0000
Black or African American4217
White313140102
More than one race0000
Unknown or Not Reported131923
Region of Enrollment
Region of Enrollment(participants)Cohort 1: HER2 OverexpressingCohort 1a: HER2 OverexpressingCohort 2: HER2 MutatedTotal
Netherlands1081331
United States19133567
Japan1232338
France031518
Spain814527
08

Study locations

21 sites
  • University of California San Diego (UCSD)
    La Jolla, California 92093, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine at St. Louis
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • Institut Gustave Roussy
    Villejuif, ile-de-France 94805, France
  • Centre Leon Berard
    Lyon, Rhne 69008, France
  • Hôpital Nord - CHU Marseille
    Marseille, 12915, France
  • CHU Larrey
    Toulouse, 31059, France
  • Hôpital Larrey, CHU-Toulouse
    Toulouse, 31059, France
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Kindai University Hospital
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Shizuoka Cancer Center
    Nagaizumi, Sunto-gun 411-8777, Japan
  • National Cancer Center Hospital
    Chuo Ku, Tokyo 104-0045, Japan
  • Netherlands Cancer Institute
    Amsterdam, 1066CX, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Publications

  • Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Perol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Janne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. PubMed 34534430 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in May 2021, 35 months.

Results were first posted in May 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2018
First posted
Apr 23, 2018
StartActual
May 21, 2018
Primary completionActual
May 3, 2021
CompletionActual
Apr 17, 2024
Results first posted
May 17, 2022
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03505710
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 23, 2018
Start date
May 21, 2018
Primary completion
May 3, 2021
Completion
Apr 17, 2024
Results posted
May 17, 2022
Last update
May 30, 2025

Study contacts

Global Team Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion